Necrotising enterocolitis in a newborn infant treated with octreotide for chylous effusion: is octreotide safe?
congenital disorders
gastrointestinal system
safety
unwanted effects / adverse reactions
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
11 Feb 2020
11 Feb 2020
Historique:
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
3
11
2020
Statut:
epublish
Résumé
Octreotide is a somatostatin analogue used for treating congenital chylothorax and congenital hyperinsulinism in infants. By increasing splanchnic arteriolar resistance and decreasing gastrointestinal blood flow, octreotide indirectly reduces lymphatic flow in chylous effusions.Splanchnic ischaemia following octreotide predisposes infants to necrotising enterocolitis (NEC). Although NEC occurrence in infants treated with octreotide for hyperinsulinaemic hypoglycaemia has been reported widely, its incidence in infants with chylothroax is low. We describe a case of congenital chylothorax in a preterm infant who had poor response to thoracentesis. Although octreotide initiation lead to resolution of chylothorax, he developed NEC. Cessation of octreotide and medical management resulted in rapid resolution of NEC. Since octreotide is generally used as the first-line treatment for chylous effusion, the risk of NEC should be considered, especially when the dosage is increased. Infants on octreotide should be closely observed for early signs and symptoms of NEC to avert surgical emergency.
Identifiants
pubmed: 32051156
pii: 13/2/e232062
doi: 10.1136/bcr-2019-232062
pmc: PMC7021135
pii:
doi:
Substances chimiques
Gastrointestinal Agents
0
Octreotide
RWM8CCW8GP
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Medicine (Baltimore). 2017 Jul;96(29):e7594
pubmed: 28723800
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Pediatr Neonatol. 2016 Apr;57(2):127-32
pubmed: 26315047
Indian Pediatr. 2015 Dec;52(12):1051-9
pubmed: 26713990
Mayo Clin Proc. 2009 Feb;84(2):129-33
pubmed: 19181646
Digestion. 1999 Mar-Apr;60(2):132-40
pubmed: 10095154
Pediatr Blood Cancer. 2017 Aug;64(8):
pubmed: 28205374
J Perinatol. 2015 May;35(5):384-6
pubmed: 25917021
N Engl J Med. 1996 Jan 25;334(4):246-54
pubmed: 8532003
Pharmacoepidemiol Drug Saf. 2017 Jan;26(1):26-31
pubmed: 27910218
J Paediatr Child Health. 2004 Sep-Oct;40(9-10):585-8
pubmed: 15367160
Pediatr Diabetes. 2010 Mar;11(2):142-7
pubmed: 19558634
Horm Res Paediatr. 2016;86(2):131-136
pubmed: 26867223
Pediatr Crit Care Med. 2004 Jul;5(4):356-7
pubmed: 15215005
Cochrane Database Syst Rev. 2010 Sep 08;(9):CD006388
pubmed: 20824848
J Pediatr Surg. 2008 Jun;43(6):1209-10
pubmed: 18558210
Intensive Care Med. 2006 May;32(5):650-7
pubmed: 16532329
Acta Chir Scand. 1979;145(7):443-46
pubmed: 161458
Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24
pubmed: 21445948